Freya Biosciences ApS: Financial statements 2021
CVR: 41257547
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
Freya Biosciences ApS (CVR 41257547) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK -5,460,126 and a net result of DKK -20,406,277. Equity in the 2021 report amounted to DKK 28,411,334. The solvency ratio was 87.8%.
- Revenue
- DKK 0
- Gross Profit
- DKK -5,460,126
- Profit/Loss
- DKK -20,406,277
- Equity
- DKK 28,411,334
- Total Assets
- DKK 32,366,790
Official annual report
Find more companies like Freya Biosciences ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
As of July 15, 2021, EY Godkendt Revisionspartnerselskab has been appointed auditor of Freya Biosciences ApS.
Freya Biosciences ApS has published its interim report for the period March 23, 2020 – December 31, 2020.
About Freya Biosciences ApS
Freya Biosciences ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2020. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Colleen Denise Acosta. The board consists of Peter Finsel Bisgaard (chair), Claudia Maria Colciago, Colleen Denise Acosta and David Lawrence Stern. The company's owners include Danmarks Eksport- og Investeringsfond, OMX Ventures Fund I, LLC and Sofinnova Capital IX. The company has 18 employees (2026). In 2025, the company reported a gross profit of DKK -14,130,000 and a net result of DKK -92,714,000 compared with DKK -85,434,294 the year before. Equity in the 2025 report amounted to DKK 72,025,000.